Article
Oncology
Jonathan M. Loree, Yucai Wang, Muddassir A. Syed, Alexey Sorokin, Oluwadara Coker, Joanne Xiu, Benjamin A. Weinberg, Ari M. Vanderwalde, Anteneh Tesfaye, Victoria M. Raymond, Benjamin Miron, Gabi Tarcic, Ori Zelichov, Russell R. Broaddus, Patrick Kwok Shing Ng, Kang Jin Jeong, Yiu Huen Tsang, Gordon B. Mills, Michael J. Overman, Axel Grothey, John L. Marshall, Scott Kopetz
Summary: The study identified a high prevalence of atypical RAS mutations in colorectal cancer patients, which were associated with poor prognosis. Activating atypical variants were the most common in clinical cohorts, providing the best evidence to guide treatment.
CLINICAL CANCER RESEARCH
(2021)
Article
Oncology
Lily V. Saadat, Thomas Boerner, Debra A. Goldman, Mithat Gonen, Timothy L. Frankel, Efsevia Vakiani, T. Peter Kingham, William R. Jarnagin, Alice C. Wei, Kevin C. Soares, David B. Solit, Michael I. D'Angelica
Summary: RAS mutations are prognostic for mCRC patients. KRAS exon 3/4 mutations are rare and may be associated with a more favorable prognosis, but the difference in oncologic outcomes based on the mutated exon appears to be smaller than previously reported.
ANNALS OF SURGICAL ONCOLOGY
(2021)
Article
Oncology
Kun-Han Lee, Wei-Shone Chen, Jeng-Kai Jiang, Shung-Haur Yang, Huann-Sheng Wang, Shih-Ching Chang, Yuan-Tzu Lan, Chun-Chi Lin, Hung-Hsin Lin, Sheng-Chieh Huang, Hou-Hsuan Cheng, Yee Chao, Hao-Wei Teng
Summary: Metastatic middle/low rectal cancer shows lower efficacy in anti-EGFR treatment compared to left-sided colon cancer, both in terms of progression-free survival, overall survival, and overall response rates for both first-line and non-first-line treatment. TCGA analysis reveals genetic heterogeneity in rectal tumors, showing shared features with both left- and right-sided colon cancer.
BRITISH JOURNAL OF CANCER
(2021)
Article
Gastroenterology & Hepatology
Serdar Arici, Jamshid Hamdard, Abdullah Sakin, Selma Sengiz Erhan, Muhammed Mustafa Atci, Ruhper Cekin, Burcu Saka, Emin Kose, Tuba Saydam, Caglayan Geredeli, Sener Cihan, Ahmet Bilici
Summary: This study investigated the RAS discordance between initial and recurrent metastasectomy specimens in mCRC patients treated with chemotherapy plus biological agents. The results suggest that re-biopsy is necessary for optimal second-line treatment decision in mCRC patients, especially in those with wild-type RAS mCRC.
COLORECTAL DISEASE
(2021)
Article
Oncology
Hideaki Bando, Yoshiaki Nakamura, Hiroya Taniguchi, Manabu Shiozawa, Hisateru Yasui, Taito Esaki, Yoshinori Kagawa, Tadamichi Denda, Taroh Satoh, Kentaro Yamazaki, Yu Sunakawa, Takeshi Kato, Masahiro Goto, Satoshi Yuki, Tomohiro Nishina, Eiji Oki, Eiji Shinozaki, Nobuhisa Matsuhashi, Naoki Takahashi, Akihito Tsuji, Koushiro Ohtsubo, Masashi Wakabayashi, Takashi Ikeno, Masayuki Hata, Justin Odegaard, Takayuki Yoshino
Summary: The relationship between metastatic site and ctDNA detection was investigated in patients with limited-extent metastatic colorectal cancer (mCRC). The results showed that the metastatic site had an impact on ctDNA detection.
JCO PRECISION ONCOLOGY
(2022)
Article
Oncology
Simonetta M. Leto, Martina Ferri, Francesco Sassi, Eugenia R. Zanella, Francesca Cottino, Valentina Vurchio, Irene Catalano, Alessandro Ferrero, Caterina C. Zingaretti, Caterina Marchio, Elena Grassi, Livio Trusolino, Andrea Bertotti
Summary: In this study, researchers aimed to find rational combinations to enhance the efficacy of the anti-EGFR antibody cetuximab in patients with RAS wild-type metastatic colorectal cancer (mCRC) by disrupting adaptive dependencies on antiapoptotic molecules. Through experiments conducted in patient-derived xenografts (PDX) and organoids (PDXO), they found that concomitant blockade of BCL-XL, an antiapoptotic protein, precipitated cell death and led to more pronounced tumor regressions in combination with cetuximab.
CLINICAL CANCER RESEARCH
(2023)
Article
Oncology
Benny Vittrup Jensen, Jakob Schou, Mette Yilmaz, Helle H. Johannesen, Kristin Skougaard, Dorte Linnemann, Estrid Hogdall, Finn O. Larsen, Julia S. Johansen, Per Pfeiffer, Dorte L. Nielsen
Summary: This study investigated the use of cetuximab and irinotecan in third-line treatment for mCRC patients, regardless of RAS or BRAF mutation status, and achieved certain efficacy. Shortening the treatment time while maintaining good treatment outcomes.
INTERNATIONAL JOURNAL OF CANCER
(2021)
Article
Oncology
Alberto Sobrero, Heinz-Josef Lenz, Cathy Eng, Werner Scheithauer, Gary Middleton, Wenfeng Chen, Regina Esser, Johannes Nippgen, Howard Burris
Summary: The study investigated the efficacy of cetuximab plus irinotecan in RAS-wild-type metastatic colorectal cancer patients as second-line treatment, showing improvements in progression-free survival, objective response rate, and quality of life. Additionally, almost half of patients in the irinotecan arm received poststudy cetuximab therapy.
Article
Oncology
Daniele Rossini, Carlotta Antoniotti, Sara Lonardi, Filippo Pietrantonio, Roberto Moretto, Lorenzo Antonuzzo, Alessandra Boccaccino, Federica Morano, Marco Brugia, Carmelo Pozzo, Federica Marmorino, Francesca Bergamo, Emiliano Tamburini, Alessandro Passardi, Giovanni Randon, Sabina Murgioni, Beatrice Borelli, Angela Buonadonna, Mirella Giordano, Gabriella Fontanini, Veronica Conca, Vincenzo Formica, Massimo Aglietta, Roberto Bordonaro, Giuseppe Aprile, Gianluca Masi, Luca Boni, Chiara Cremolini
Summary: The intensification of upfront chemotherapy backbone with panitumumab does not provide additional benefit in terms of treatment activity in patients with RAS and BRAF wt mCRC, while increasing gastrointestinal toxicity.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Oncology
Wentao Tang, Yu Liu, Meiling Ji, Tianyu Liu, Yijiao Chen, Aobo Zhuang, Yihao Mao, Wenju Chang, Ye Wei, Li Ren, Jianmin Xu
Summary: In this study, regardless of metastases resection or no resection, RAS and BRAF mutations were associated with a poor prognosis. Resection of metastases could bring survival benefits for patients regardless of RAS/BRAF status.
ANNALS OF SURGICAL ONCOLOGY
(2022)
Article
Oncology
Giovanni Randon, Giulia Maddalena, Marco Maria Germani, Chiara Carlotta Pircher, Paolo Manca, Francesca Bergamo, Mirella Giordano, Caterina Sposetti, Aldo Montagna, Guglielmo Vetere, Luca Zambelli, Cosimo Rasola, Alessandra Boccaccino, Filippo Pagani, Margherita Ambrosini, Marco Massafra, Gabriella Fontanini, Massimo Milione, Matteo Fassan, Chiara Cremolini, Sara Lonardi, Filippo Pietrantonio
Summary: This study identified rare genomic alterations beyond RAS and BRAFV600E mutations that drive primary resistance to anti-EGFR therapy in metastatic colorectal cancer, highlighting the need for further investigation to maximize the benefit of EGFR blockade strategies.
JCO PRECISION ONCOLOGY
(2022)
Article
Oncology
Stefano Mariani, Marco Puzzoni, Riccardo Giampieri, Pina Ziranu, Valeria Pusceddu, Clelia Donisi, Mara Persano, Giovanna Pinna, Erika Cimbro, Alissa Parrino, Dario Spanu, Andrea Pretta, Eleonora Lai, Nicole Liscia, Alessio Lupi, Enrica Giglio, Grazia Palomba, Milena Casula, Marina Pisano, Giuseppe Palmieri, Mario Scartozzi
Summary: This study investigated the efficacy of liquid biopsy-driven cetuximab rechallenge in a selected population of CRC patients with RAS and BRAF WT. The results showed that liquid biopsy-driven cetuximab rechallenge was effective and consistent with previous phase II studies. In addition to molecular selection, a longer anti-EGFR free interval was confirmed as an important predictor for this therapeutic option.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Yi-Chia Su, Chih-Chien Wu, Chien-Chou Su, Meng-Che Hsieh, Ching-Lan Cheng, Yea-Huei Kao Yang
Summary: This study assessed the effectiveness of bevacizumab and cetuximab therapies in patients with metastatic colorectal cancer who did not undergo primary tumor resection. The results showed that cetuximab-based therapy had significantly better survival and conversion surgery rates compared to bevacizumab-based therapy in these patients.
Article
Oncology
Catherine G. Tran, Paolo Goffredo, Sarah L. Mott, Mohammed O. Suraju, Julia F. Kohn, Aditi Mishra, Jean-Nicolas Vauthey, Imran Hassan
Summary: This study investigates the impact of laterality, microsatellite instability (MSI), and KRAS status on conditional overall survival (COS) in colon cancer. The results show that mKRAS is associated with worse COS, suggesting a more aggressive biological behavior.
ANNALS OF SURGICAL ONCOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Jiuna Zhang, Xiaoyu Jiang, Jie Yin, Shiying Dou, Xiaoli Xie, Ting Liu, Yijun Wang, Shuling Wang, Xue Zhou, Dongxuan Zhang, Huiqing Jiang
Summary: RNF141 plays an oncogenic role in colorectal cancer by upregulating KRAS activity, which promotes tumor growth, cell proliferation, migration, and apoptosis by interacting with KRAS to induce its activation and enrichment on the plasma membrane.
